Projekte
Suche in 1147 Projekten:
1147 Projekt(e)
Assessing a ctDNA and PET-oriented therapy in patients with DLBCL multicenter, open-label, phase II trial
08.06.2021Despite advances in the clinical care of patients with DLBCL and in understanding the biology of this disease, cure rates have remained the same since the introduction of rituximab to CHOP chemotherapy, and RCHOP chemoimmunotherapy remains the standa...
Klinische Forschung - 08.06.2021 - 31.12.2030
Laufend
Projektleitung: Hitz Felicitas
Mitarbeiter/innen: Harder Anja, Quinter Janine
Application of smart sensor insoles for assessment of gait parameters and correlation to patient-reported outcomes in hip arthroplasty patients
01.06.2021Gait parameters like gait velocity, stride length, cadence or load symmetry contribute to a successful outcome after total hip arthroplasty (THA) and can be addressed through targeted physiotherapeutic training programs. Instrumented gait analysis i...
Grundlagenforschung - 01.06.2021 - 30.06.2025
Geplant
Projektleitung: Ladurner Andreas
Mitarbeiter/innen: Giesinger Karlmeinrad
Analysis of the maturation of the peripheral nervous system in neonates, infants and children using high-resolution ultrasound imaging
01.06.2021During early childhood nerve conduction velocity (NCS) increases from 20m/s at the time of birth to almost adult values of 50m/s at two years of age. How this increase in NCS is correlated to the structural maturation of the peripheral nerves is unkn...
Klinische Forschung - 01.06.2021 - 01.06.2023
Automatisch geschlossen
Mitarbeiter/innen: Broser Philip
SAKK 67/20 Open-label single-stage phase 1B study of the new micellar docetaxel compound Docecal in patients with advanced castra-tion-resistant prostate cancer
28.05.2021Background: Docetaxel, a semi-synthetic analogue of paclitaxel, is one of the most widely used human anti-cancer agents. Docetaxel and paclitaxel belong to a group of cytotoxic agents called tax-anes. Docetaxel has been marketed worldwide by Sanofi-...
Klinische Forschung - 28.05.2021 - 31.12.2024
Abgeschlossen
Projektleitung: Fischer Stefanie
Mitarbeiter/innen: Aeschbacher Anette
Pilot study on cognitive and social function measures for early detection of progressive neurocognitive disorders in Switzerland
12.05.2021
Klinische Forschung - 12.05.2021 - 15.09.2022
Abgeschlossen
Projektleitung: Felbecker Ansgar
Profiling of quitting trajectories during smoking cessation attempt (SMOKEPROFILE-Study)
01.05.2021The study hypothesis is twofold. First, we hypothesize that investigating daily tobacco consumption of smokers attempting to quit can be used to characterize clinically relevant quitting trajectories which can be used to predict quitting success. Our...
Grundlagenforschung - 01.05.2021 - 30.12.2023
Automatisch geschlossen
Projektleitung: Baty Florent
Mitarbeiter/innen: Brutsche Martin, Bösch Maximilian, Pohle Susanne
Comparison of the effect of outdoor eccentric versus indoor concentric exercise training on physical capacity and qualityof-life in patients with advanced COPD (DOWNHILL-study)
01.05.2021Patients with chronic obstructive pulmonary disease (COPD) often suffer from cardio-pulmonary limitations, which makes them avoid exercise training. However, exercise training is explicitly recommended for COPD patients as physical activity (PA) is k...
Grundlagenforschung - 01.05.2021 - 30.04.2025
Laufend
Projektleitung: Bösch Maximilian
Mitarbeiter/innen: Baty Florent, Brutsche Martin, Benz Gabriel
Response to COVID-19 vaccination and COVID-19 infections after vaccination in patients with haematological malignancies
01.05.2021The prevalence and mortality of COVID-19 are higher in patients with haematological malignancies (HM) compared to the general population (Vijenthira et al. 2020). Two SARS-CoV-2 messenger RNA (mRNA) vaccines have been approved by Swissmedic, both are...
Klinische Forschung - 01.05.2021 - 01.10.2022
Abgeschlossen
Projektleitung: Silzle Tobias
Mitarbeiter/innen: Fischer Stefanie, Kahlert Christian, Albrich Werner
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 in Combination with Acalabrutinib in Subjects with Relapsed/Refractory Dif-fuse Large B-cell Lymphoma or Relapsed/Refractory Chronic Lymphocytic Leukemia
22.04.2021Aclabrutinib wird in Kombination mit KRT 232 bei R/R CLL und de novo R/R DLBCL jeweils TP 53 WT und BTK naiv eingesetzt. Initial Dosisescalations-stufe (Ib), anschlies-send Phase-II mit RP2D. Primärer Endpunkt: Dosisfin-dung/ Safety ; Efficacy in Ph...
Klinische Forschung - 22.04.2021 - 20.05.2030
Abgeschlossen
Projektleitung: Hess Dagmar
Mitarbeiter/innen: Scherrer Julia, Müller Fiona
Bayer 20324
14.04.2021TRK fusion cancer is rare but presents as a variety of solid tumors. Larotrectinib is a highly selective TRK inhibitor that, in a pooled analysis of patients in phase 1/2 clinical trials, demonstrated an effective and sustained response in the majori...
Klinische Forschung - 14.04.2021 - 21.04.2021
Automatisch geschlossen
A multicenter, non-randomized, open-label phase 1b study to determine the maximum tolerated and recommended phase 2 dose of the ATR Inhibitor BAY 1895344 in combination with pembrolizumab and characterize its safety, tolerability, pharmacokinetics and preliminiary anti-tumor activity in patients with advanced solid tumors
14.04.2021BAY-1895344 und Pembrolizumab bei ausgewählten Tumoren mit genetischen Alterationen von ATM.
Klinische Forschung - 14.04.2021 - 21.02.2022
Automatisch geschlossen
Projektleitung: Jörger Markus
ON-TRK: PrOspective Non-interventional study in patients with locally advanced or metastatic TRK fusion cancer treated with larotrectinib
14.04.2021TRK fusion cancer is rare but presents as a variety of solid tumors. Larotrectinib is a highly selective TRK inhibitor that, in a pooled analysis of patients in phase 1/2 clinical trials, demonstrated an effective and sustained response in the ma...
Klinische Forschung - 14.04.2021 - 31.12.2025
Laufend
Projektleitung: Jörger Markus
Mitarbeiter/innen: Kern Julia, Quinter Janine
Diabetescoach
01.04.2021Personal Health Coaching für Patient*innen mit Diabetes Typ 2
Klinische Forschung - 01.04.2021 - 31.12.2030
Laufend
Projektleitung: Bilz Stefan
Mitarbeiter/innen: Räss Andrea, Grillmayr Victoria
MK-7902-005 A Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects with Selected Solid Tumors (LEAP-005)
17.03.2021The rationale for this study comes from preclinical models, in which lenvatinib decreased the tumor-associated macrophage (TAM) population, which is known as an immune-regulator in the tumor microenvironment. The decrease in TAM population was accomp...
Klinische Forschung - 17.03.2021 - 07.05.2030
Laufend
Projektleitung: Fischer Stefanie
Mitarbeiter/innen: Donno Monica, Quinter Janine
A Study to Evaluate Imetelstat (GRN163L) in Transfu-sion-Dependent Subjects with IPSS Low or Intermedi-ate-1 Risk Myelodysplastic Syndrome (MDS) that is Re-lapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment
15.03.2021A Study to Evaluate Imetelstat (GRN163L) in Transfu-sion-Dependent Subjects with IPSS Low or Intermedi-ate-1 Risk Myelodysplastic Syndrome (MDS) that is Re-lapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment
Klinische Forschung - 15.03.2021 - 07.04.2030
Laufend
Projektleitung: Silzle Tobias
Mitarbeiter/innen: Driessen Christoph, Fehr Martin, Hitz Felicitas, Lehmann Thomas
An open-label Phase 1/2a study of oral BAL101553
08.03.2021Frühe Phase-II Studie zur Behandlung von IDH-Wildtyp Glioblastomen oder IDH-mutierten Astrozytomen WHO Grad IV nach Progression (jede Linie) mit Lisavanbulin als orale Monotherapie mit geringen Nebenwirkungen. Die Wirksamkeit der Behandlung mit Lisav...
Klinische Forschung - 08.03.2021 - 16.02.2030
Abgeschlossen
Projektleitung: Hundsberger Thomas
SAKK 17/18 Origin
05.03.2021A significant number of patients with malignant pleural mesothelioma (MPM) and non-small cell lung cancer (NSCLC) are not cured with available treatments and will eventually relapse. After relapse treatment options are limited. Preclinical in vitro s...
Klinische Forschung - 05.03.2021 - 12.12.2024
Laufend
Projektleitung: Jörger Markus
Atezolizumab in combination with Bevacizumab and Chemotherapy versus Bevacizumab and Chemotherapy in recurrent ovarian cancer- a randomized Phase III trial An ENGOT Trial
04.03.2021This study will evaluate the efficacy and safety of atezolizumab plus bevacizumab and chemotherapy compared with placebo plus bevacizumab and chemotherapy in patients with recurrent ovarian-, fallopian tube, or primary peritoneal cancer with 1st or 2...
Klinische Forschung - 04.03.2021 - 24.12.2025
Laufend
Projektleitung: Hasler-Strub Ursula
CardioOnco - Diagnosing Preclinical Cardiac Dysfunction in Adult Childhood Cancer Survivors ‒ The CardioOnco study
01.03.2021We aim to: 1. Assess preclinical cardiac dysfunction longitudinally using 2-dimensional (2D) and 3-dimensional (3D) conventional and 2D speckle tracking echocardiography. 2. Assess cardiopulmonary fitness using cardiopulmonary exercise testing. 3....
Klinische Forschung - 01.03.2021 - 31.12.2030
Laufend
Projektleitung: Scheler Eva
Mitarbeiter/innen: Schneider Irene
Outcome von Patienten mit Kopf-Hals-Malignomen in der Hals-Nasen- Ohrenklinik am Kantonsspital St.Gallen
01.03.2021Die Hals-Nasen-Ohren Klinik am Kantonsspital St.Gallen nimmt zusammen mit der Klinik für Radio-Onkologie und der Klinik für Medizinische Onkologie/Hämatologie eine Zentrumsfunktion in der Ostschweiz für die Behandlung von Kopf-Hals-Tumorpatienten ein...
Klinische Forschung - 01.03.2021 - 09.03.2022
Automatisch geschlossen